BioHarvest Secures 20-Ton CDMO Contract; 2027 Fragrance Production Catalyst for BHST
Aug 11, 2026, 6:34 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The 20-ton CDMO deal establishes a tangible recurring-revenue framework and signals scale that could improve gross margins once production ramps. The cash-position improvement and AI/grant support reduce capital risk, while saffron and Tate & Lyle collaborations broaden BHST’s high-value pipeline. However, near-term EBITDA guidance revisions introduce execution risk, so the reaction may be upside-biased but tempered by profitability concerns.
AI summary
What happened, with direct paths to the underlying reporting
BioHarvest reported 2Q26 revenue of $8.8M with a 58% gross margin and announced a first CDMO contract to produce a 20-ton fragrance ingredient over two years, potentially starting in 2027. The deal, along with a $1.4M IIA grant and saffron collaboration, signals a shift toward recurring manufacturing revenue while VINIA remains a slower-growing consumer business. 2026 guidance was revised to reflect capex shift, implying near-term margin headwinds but longer-term upside from CDMO scale.
BioHarvest signs first CDMO contract for 20-ton fragrance production over two years.
Q2 2026 revenue $8.8M; gross margin 58%; net loss continues but improving.
$16.25M cash on hand as of 6/30/2026; funding capex and manufacturing expansion.
Stage 2 saffron program valued at $1.125M; 25% ownership; IIA grant $1.4M.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
